Bluejay Diagnostics (NASDAQ:BJDX) is a medical technology company focused on the development and commercialization of non-invasive breath-based diagnostics. Leveraging proprietary sensor arrays and data analytics, the company’s core platform is designed to detect volatile organic compounds (VOCs) and other biomarkers in exhaled breath. This approach aims to enable rapid, point-of-care screening and monitoring for respiratory diseases, oncology indications and infectious agents without the need for blood draws or complex laboratory infrastructure.
The company’s initial product candidates are centered on a handheld breathalyzer device paired with single-use disposable cartridges that collect and analyze breath samples in real time. Bluejay Diagnostics is advancing clinical studies to validate the sensitivity and specificity of its technology for conditions such as early-stage lung cancer, chronic obstructive pulmonary disease (COPD), and select viral or bacterial respiratory infections. By integrating miniaturized sensor technology with machine learning algorithms, the platform seeks to distinguish disease signatures at low biomarker concentrations, supporting both diagnostic and triage workflows in outpatient, urgent care and hospital settings.
Founded in 2018 and headquartered in Medford, Massachusetts, Bluejay Diagnostics emerged from collaborative research programs involving academic institutions and technology incubators. Over its history, the company has secured partnerships with medical centers and research organizations in North America and Europe to conduct multi-center validation studies. This global footprint is intended to facilitate regulatory filings and market entry across diverse healthcare systems, with an emphasis on affordability and ease of use in decentralized environments.
Bluejay Diagnostics is led by a management team with deep experience in molecular diagnostics, medical device engineering and commercialization. The executive leadership includes industry veterans who have previously brought diagnostic platforms through regulatory approval and commercial launch. Supported by a board of directors and scientific advisors, the company continues to expand its pipeline and refine its breath analysis technology as it moves toward pivotal clinical trials and regulatory submissions.
